The outcome of primary mediastinal B-cell lymphoma in a single center experience
Conclusions The vast majority of PMBCL patients are susceptible to immunochemotherapy with a high response rate achieved after R-DA-EPOCH/R-CHOP regimens. AHSCT seems to be an option for fit patients with disease chemosensitivity.
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research
More News: Chemotherapy | Hematology | Lymphoma | PET Scan | Stem Cell Therapy | Stem Cells | Transplants